Orion Infusion Limited (DSE:ORIONINFU)

Market Cap	6.05B -15.8%
Revenue (ttm)	647.55M -4.1%
Net Income	35.51M -13.9%
EPS	1.74 -13.9%
Shares Out	20.36M
PE Ratio	170.45
Forward PE	n/a
Dividend	2.00 (0.67%)
Ex-Dividend Date	Dec 2, 2025

Volume	363,057
Open	n/a
Previous Close	297.30
Day's Range	285.00 - 297.50
52-Week Range	285.00 - 587.50
Beta	-1.65
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Orion Infusion

Orion Infusion Limited manufactures and sells large volume parenteral and other lifesaving injectable products in Bangladesh. The company offers I.V. rehydration, electrolyte, and acidosis solutions; ranitidine I.V. infusion; anti-microbial products; metronidazole I.V; pure steam generated fluids; and amino acids solution. It also provides sterile and nonpyrogenic solution, such as Dextrolac, Dianak, Hartman, Manisol, Plasmasol, and Proliv; hypertonic solution, including Dextrosal, Electrodex-10, Fructose – 10, Orlev, Ortac; Dextropac, an isoto...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 563
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ORIONINFU

Financial Performance

In fiscal year 2025, Orion Infusion's revenue was 664.92 million, a decrease of -19.64% compared to the previous year's 827.42 million. Earnings were 35.02 million, a decrease of -17.27%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 6, 2026

Data Sources Report a data error